Effect of monthly intravenous cyclophosphamide in rapidly deteriorating multiple sclerosis patients resistant to conventional therapy

Fourteen consecutive clinically definite relapsing-remitting multiple sclerosis (MS) patients were treated with monthly intravenous cyclophosphamide (CTX) for 6 months. All had experienced severe clinical deterioration during the 12 months prior to treatment with CTX despite treatment with conventio...

Full description

Saved in:
Bibliographic Details
Published in:Multiple sclerosis 2001-06, Vol.7 (3), p.185-188
Main Authors: Khan, Omar A, Zvartau-Hind, Marina, Caon, Christina, Din, Moeen U, Cochran, Mickey, Lisak, Deena, Tselis, Alexandros C, Kamholz, John A, Garbern, James Y, Lisak, Robert P
Format: Article
Language:English
Subjects:
Adult
Biological and medical sciences
Cyclophosphamide - administration & dosage
Female
Humans
Immunomodulators
Immunosuppressive Agents - administration & dosage
Injections, Intravenous
Male
Medical sciences
Middle Aged
Multiple Sclerosis - drug therapy
Pharmacology. Drug treatments
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Fourteen consecutive clinically definite relapsing-remitting multiple sclerosis (MS) patients were treated with monthly intravenous cyclophosphamide (CTX) for 6 months. All had experienced severe clinical deterioration during the 12 months prior to treatment with CTX despite treatment with conventional immunomodulating agents and intravenous methylprednisolone. Treatment with CTX led to improvement and neurologic stability within 6 months which was sustained for at least 18 months after the onset of treatment with CTX. Therapy with CTX was well tolerated. CTX may be of benefit in MS patients who experience rapid clinical worsening and are resistant to conventional therapy.
ISSN:1352-4585
1477-0970
DOI:10.1177/135245850100700309